RecruitingNot ApplicableNCT05667519

Prevention of Pacemaker Lead Induced Tricuspid regurgitAtion by Transesophageal eCho guidEd Implantation (PLACE)


Sponsor

LMU Klinikum

Enrollment

324 participants

Start Date

Oct 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This is the first randomized controlled trial comparing transesophageal echocardiography + fluoroscopy guided lead implantation vs. standard lead implantation guided by fluoroscopy only. Patients are randomized 1:1 in the two groups and followed up for up to 3 years.


Eligibility

Min Age: 18 Years

Inclusion Criteria1

  • indication for right ventricular lead implantation according to current guidelines

Exclusion Criteria6

  • preexisting tricuspid regurgitation ≥ grade 2
  • other severe heart valve disease
  • history of tricuspid valve treatment
  • preexisting right ventricular lead
  • chronic dialysis
  • contraindication for transesophageal echocardiography

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREAdditional guidance of lead implantation by transesophageal echocardiography

Transesophageal echocardiography guidance of lead implantation targeting a stable lead position in a tricuspid valve commissure (preferentially postero-septal) and an apical ventricular lead position


Locations(1)

LMU Klinikum

Munich, Bavaria, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05667519


Related Trials